Lipophilic 1-β-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 12, 1996, Pages 723-726

  Schwendener, R A ^a   Schott, H ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

L1210 leukemia; lipophilic cytosine arabinoside derivatives; liposomes; oral therapy

Indexed keywords

CYTARABINE; CYTARABINE DERIVATIVE; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; LEUKEMIA L 1210; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029806234     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01209119     Document Type: Article

References (19)

1. Chabner BA (1990) Cytidine analogues In: Chabner BA, Collins JM (eds), Cancer Chemotherapy, Principles and Practice, Lippincott, Philadelphia, pp 154-179
2. Ho DHW, Frei E (1971) Clinical pharmacology of 1-β-D-arabinofuranosylcylosine. Clin Pharmacol Ther 12:944-954
3. 4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J Pharm Pharmacol 47:282-288
4. 4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer 71:957-962
5. 4-hexadecyl-1-β-D-arabinofuranosylcytosine. Br J Cancer 72:1067-1073
6. 4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937. Cancer Chemother Pharmacol 36:483-492
7. Kodama K, Morozumi M, Saitoh K, Kuninaka A, Yoshino H, Saneyoshi M (1989) Antitumor activity and pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate: an orally active derivative 1-β-D-arabinofuranosylcytosine. Jpn J Cancer Res 80:679-685
8. Koga K, Iizuka E, Sato A, Ekimoto H, Okada M (1995) Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice. Cancer Chemother Pharmacol 36:459-462
9. 4-palmitoyl-1-β-n-arabino-furanosylcytosine. Cancer Chemother Pharmacol 17:161-164
10. Ohno R, Tatsumi N, Hirano M, Imai K, Mizoguchi H, Nakamura T, Kosaka M and 10 other authors (1991) Treatment of myelodysplastic syndromes with orally administered 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate. Oncology 48:451-455
11. 4-acyl and 2,2′-anhydro-3′-O-acyl derivatives as potential prodrugs. J Med Chem 25:171-178
12. Rubas W, Supersaxo A, Weder HG, Hartmann HR, Hengartner H. Schott H, Schwendener RA (1986) Treatment of murine L1210 leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 37:149-154
13. Schleyer E, Braess J, Ramsauer B, Unterhalt M, Kaufmann C, Wilde S, Schüssler M, Hiddemann W (1995) Pharmacokinetics of AraCMP-stearate (YNK01): phase I study of the oral Ara-C derivative. Leukemia 9:1085-1090
14. 4-hexadecyl-1-β-D-arabinofuranosylcytosine conjugates on L1210 leukemia. Anti-cancer Drug Design (in press).
15. Schott H, Häussler MP, Schwendener RA (1994) Synthese von 4-Alkylcytosinnucleosiden und deren cytostatische Wirkung im L1210 Leukämiemodell der Maus. Liebigs Ann Chem 465-470
16. 4-hexadecyl-1-β-D-arabinofuranosylcytosine. Int J Cancer 51:466-469
17. 4-octadecyl-1-β-D-arabinofuranosylcytosine in liposomal preparations. J Liposome Res 5:27-47
18. 4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine (Ara-C). J Cancer Res Clin Oncol 122:102-108
19. Ueda T, Kamiya K, Urasaki Y, Walaya S, Kawai Y, Tsutani H, Sugiyama M, Nakamura T (1994) Clinical pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate, an orally administered long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 54:109-113